ES2947312T3 - Conjugados para la edición dirigida de la superficie celular - Google Patents

Conjugados para la edición dirigida de la superficie celular Download PDF

Info

Publication number
ES2947312T3
ES2947312T3 ES17821402T ES17821402T ES2947312T3 ES 2947312 T3 ES2947312 T3 ES 2947312T3 ES 17821402 T ES17821402 T ES 17821402T ES 17821402 T ES17821402 T ES 17821402T ES 2947312 T3 ES2947312 T3 ES 2947312T3
Authority
ES
Spain
Prior art keywords
sialidase
conjugate
her2
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17821402T
Other languages
English (en)
Spanish (es)
Inventor
Melissa Gray
Elliot C Woods
Han Xiao
Carolyn R Bertozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2947312T3 publication Critical patent/ES2947312T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Steroid Compounds (AREA)
ES17821402T 2016-07-01 2017-06-30 Conjugados para la edición dirigida de la superficie celular Active ES2947312T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357645P 2016-07-01 2016-07-01
PCT/US2017/040411 WO2018006034A1 (en) 2016-07-01 2017-06-30 Conjugates for targeted cell surface editing

Publications (1)

Publication Number Publication Date
ES2947312T3 true ES2947312T3 (es) 2023-08-04

Family

ID=60787043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17821402T Active ES2947312T3 (es) 2016-07-01 2017-06-30 Conjugados para la edición dirigida de la superficie celular

Country Status (14)

Country Link
US (2) US11459398B2 (enExample)
EP (2) EP3478314B1 (enExample)
JP (2) JP7187024B2 (enExample)
KR (2) KR102822525B1 (enExample)
CN (1) CN109641038A (enExample)
AU (2) AU2017290554B2 (enExample)
BR (1) BR112018077362A2 (enExample)
CA (1) CA3027234A1 (enExample)
DK (1) DK3478314T5 (enExample)
ES (1) ES2947312T3 (enExample)
IL (2) IL263617B2 (enExample)
MX (1) MX2018016393A (enExample)
SG (1) SG11201811719RA (enExample)
WO (1) WO2018006034A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10590198B2 (en) 2015-08-28 2020-03-17 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
GB201616006D0 (en) * 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CA3087529A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
AU2019282825A1 (en) * 2018-06-07 2020-12-10 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
CN119841953A (zh) * 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
GB201811291D0 (en) * 2018-07-10 2018-08-29 Univ Dublin City A method of predicting response to treatment in cancer patients
EP3604551A1 (en) * 2018-07-31 2020-02-05 Université de Bretagne Occidentale Complement-dependent cytotoxicity and sialylation as biomarkers for predicting clinical response to cancer treatment with antibody or derivative mediating complement activation
GB201819920D0 (en) * 2018-12-06 2019-01-23 Pneumagen Ltd Cancer treatment
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells
US20220105179A1 (en) * 2019-02-21 2022-04-07 The General Hospital Corporation Glycoengineering immunoglobulin e
KR20220032576A (ko) * 2019-07-03 2022-03-15 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 그를 사용하는 방법
CA3145672A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-cd20-antibody fusion proteins and methods of use thereof
AU2020300680A1 (en) * 2019-07-03 2022-02-03 Palleon Pharmaceuticals Inc. Recombinant sialidases and methods of using the same
AU2020299614A1 (en) * 2019-07-03 2022-02-03 Palleon Pharmaceuticals Inc. Sialidase-PD-L1-antibody fusion proteins and methods of use thereof
AU2020299543A1 (en) * 2019-07-03 2022-02-03 Palleon Pharmaceuticals Inc. Sialidase-HER2-antibody fusion proteins and methods of use thereof
JP2023526277A (ja) * 2020-05-13 2023-06-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 核酸リガンドコンジュゲートおよび細胞への送達のためのその使用
CN116368222A (zh) * 2020-07-21 2023-06-30 斯克里普斯研究学院 破坏cd28-唾液酸糖苷配体复合物以增强t细胞活化
CN116744943A (zh) * 2020-12-04 2023-09-12 达因疗法公司 抗体-寡核苷酸复合物及其用途
AU2022262794A1 (en) 2021-04-23 2023-11-02 Beth Israel Deaconess Medical Center, Inc. Glycan modified nucleic acids, methods of preparation, and therapeutic uses
US20250064921A1 (en) * 2021-12-28 2025-02-27 Cz Biohub Sf, Llc Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2620649C3 (de) 1976-05-11 1980-11-06 Behringwerke Ag, 3550 Marburg Immunologisches Adjuvans
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
FR2828386B1 (fr) 2001-08-10 2004-06-11 Jean Noel Acquaviva Ecran de vision coupe-vent
KR20090087971A (ko) 2002-11-22 2009-08-18 유 망 광범위 스펙트럼의 항-바이러스 치료제 및 예방제
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
KR102109867B1 (ko) 2006-01-24 2020-05-13 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
EP1938835A1 (en) 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
JP2013510169A (ja) 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
EP2861259A1 (en) * 2012-06-14 2015-04-22 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
UA105278C2 (ru) * 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
KR102350205B1 (ko) 2013-03-15 2022-01-14 안선 바이오파르마, 아이엔씨. 단백질 정제의 신규한 방법
US20160120961A1 (en) 2013-06-10 2016-05-05 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
WO2014201034A2 (en) 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
US20160229882A1 (en) 2013-09-17 2016-08-11 The Regents Of The University Of California Non-enzymatic, salt-mediated synthesis of polynucleic acids
US20170165334A1 (en) 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
MX378457B (es) 2014-09-10 2025-03-11 Innate Pharma Anticuerpos siglec de reacciòn cruzada.
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
WO2016200916A1 (en) 2015-06-08 2016-12-15 Ansun Biopharma, Inc. Treatment of human metapneumovirus
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US20180271997A1 (en) 2016-05-31 2018-09-27 Tianxin Wang Methods and Reagents to Treat Tumor and Cancer
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
CA3048381A1 (en) 2016-12-28 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
WO2018231661A1 (en) 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
JP2021531042A (ja) 2018-07-20 2021-11-18 アンサン バイオファーマ, インク.Ansun Biopharma, Inc. 癌細胞、免疫細胞及び腫瘍微小環境へのシアリダーゼの送達

Also Published As

Publication number Publication date
EP4218802A2 (en) 2023-08-02
NZ749410A (en) 2021-01-29
JP7496629B2 (ja) 2024-06-07
BR112018077362A2 (pt) 2019-10-01
WO2018006034A1 (en) 2018-01-04
AU2020289739A1 (en) 2021-01-21
KR20190025925A (ko) 2019-03-12
US20190248919A1 (en) 2019-08-15
JP2022176981A (ja) 2022-11-30
JP7187024B2 (ja) 2022-12-12
MX2018016393A (es) 2019-08-12
DK3478314T5 (da) 2024-07-15
IL263617A (en) 2019-02-03
KR20230142631A (ko) 2023-10-11
EP3478314A4 (en) 2020-05-27
KR102581747B1 (ko) 2023-09-22
SG11201811719RA (en) 2019-01-30
CN109641038A (zh) 2019-04-16
US20230287140A1 (en) 2023-09-14
DK3478314T3 (da) 2023-06-19
IL305907A (en) 2023-11-01
CA3027234A1 (en) 2018-01-04
AU2020289739B2 (en) 2024-08-08
EP3478314A1 (en) 2019-05-08
AU2017290554A1 (en) 2019-01-17
US11459398B2 (en) 2022-10-04
EP4218802A3 (en) 2023-09-27
IL263617B1 (en) 2023-10-01
JP2019531697A (ja) 2019-11-07
AU2017290554B2 (en) 2020-10-08
EP3478314B1 (en) 2023-03-22
KR102822525B1 (ko) 2025-06-20
US12404342B2 (en) 2025-09-02
IL263617B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
ES2947312T3 (es) Conjugados para la edición dirigida de la superficie celular
US20240000962A1 (en) Glycan-Interacting Compounds and Methods of Use
US20220169724A1 (en) Inhibitory Immune Receptor Inhibition Methods and Compositions
ES2401421T3 (es) Método y ocmposición para alterar una patología mediada por células B
NZ749410B2 (en) Conjugates for targeted cell surface editing
US20250276081A1 (en) Mucin-Active Proteases and Methods of Use
US20250121075A1 (en) Alpha-fetoprotein bioconjugates for disease treatment